A carregar...
Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date
Anthracyclines, and doxorubicin in particular, remain a mainstay of sarcoma therapy. Despite modest activity and significant toxicities, no cytotoxic monotherapy has yet yielded superior overall survival over doxorubicin for therapy of advanced soft tissue sarcomas in a randomized trial. Similarly,...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6430065/ https://ncbi.nlm.nih.gov/pubmed/30936721 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S145539 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|